New drug approval pathway benefits industry over patients, argues expert
Approval mechanisms must be grounded in patient need and population health A new UK drug approval pathway, designed to speed up the availability of new medicines, benefits industry over patients and the NHS, argues an expert in The BMJ today. The pathway aligns regulatory review by the Medicines and Healthcare products Regulatory ...

